TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

Highlights Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Equities

600329

CNE000001808

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-04-20			5-day change	1st Jan Change
40.56 ^CNY	-0.34%		-0.25%	-11.09%

Mar. 31	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025	MT
Mar. 31	Singapore Shares Remain in Red Amid Soaring Energy Costs; Rex International Plunges 20%	MT

Highlights

Mar. 31	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025	MT
Mar. 30	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Down 4% in 2025	MT
Mar. 30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Proposes Final Dividend for Fiscal Year 2025	CI
Mar. 30	Tianjin Pharmaceutical Da Ren Tang 2025 net profit down 4.4%	RE
Mar. 30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 06	Controlling Shareholder Ups Stake in Tianjin Pharmaceutical Da Ren Tang; Shares Up 3%	MT
Feb. 02	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Interim Dividend for the Financial Year Ended 31 December 2025, Payable on or About February 12, 2026	CI
Nov. 25	Tianjin Pharmaceutical Plant Receives Drug Registration Certificate	CI
25-10-31	Tianjin Pharmaceutical Da Ren Tang Q3 Profit Up 54%, Revenue Down 38%	MT
25-10-30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-30	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Proposes Interim Dividend for Fiscal Year 2025	CI
25-10-30	Tianjin Pharmaceutical Da Ren Tang's Q3 Attributable Jumps 54% in Q3	MT
25-08-14	Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Soars in Q2	MT
25-08-14	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-14	Tianjin Pharmaceutical Da Ren Tang Group Estimates Increased Attributable Profit in H1	MT
25-07-14	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2025	CI
25-07-14	Tianjin Pharmaceutical Da Ren Tang sees H1 net profit up 180-204% Y/Y	RE
25-06-30	Tianjin Pharmaceutical Da Ren Tang Completes Disposal of 12% Stake in Tianjin TSKF; Shares Up 2%	MT
25-06-27	Haleon China Co., Ltd., and Haleon CH SARL completed the acquisition of 12% stake in Sino-American Tianjin Smith Kline & French Laboratories Ltd. from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.	CI
25-06-27	Haleon plc completed the acquisition of remaining 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited.	CI
25-06-18	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Dividend for the Financial Period Ended 31 December 2024, Payable on or About 4 July 2025	CI
25-04-29	Tianjin Pharmaceutical Da Ren Tang Attributable Profit Shrinks in Q1	MT
25-04-29	Tianjin Pharma's Attributable Profit Slips 3% in Q1	MT
25-04-29	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-15	Tianjin Pharma to Dispose of Remaining 12% Stake in Tianjin TSKF Pharmaceutical	MT